Inverting the therapeutic triangle

Journal of Pediatric Gastroenterology and Nutrition

Volumn 40, Issue SUPPL. 1, 2005, Pages

  Grand, Richard J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CONFERENCE PAPER; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENTERITIS; HUMAN; IMMUNOPATHOLOGY; NUTRITION; PRIORITY JOURNAL; QUALITY CONTROL; TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; CHILD; HUMANS; INFLAMMATORY BOWEL DISEASES; REMISSION INDUCTION;

EID: 16444367362     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200504001-00031     Document Type: Conference Paper

References (17)

1. Escher JC, Taminiau JA, Nieuwenhuis EE, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflation Bowel Dis 2003;9:34-53.
2. Ferry GD, Büller HA. Mechaninisms of growth retardation, drug therapy, and nutritional support in pediatric inflammatory bowel disease: a workshop sponsored by the north American and European societies for pediatric gastroenterology and nutrition. Inflamm Bowel Dis 1995;1:313-30.
3. Hanauer SB, D'Haens G. Medical management of ulcerative colitis. In: Targan SR, Shanahan F, eds. Inflammatory Bowel Disease - from the Bench to Bedside. Eialtimore: Williams & Wilkins; 1994:545-66.
4. Bernstein CN, Shanahan F. Immunomodulatory therapy in inflammatory bowel disease. In: Targan SR, Shanahan F, eds. Inflammatory Bowel Disease - from the Bench to Bedside. Baltimore: Williams & Wilkins; 1994:503-23.
5. D'Haens G, van Deventer S, van Hogezand R, et al. Endoscopic and histologic healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease. Gasroenterology 1999;116:1029-34
6. Heuschkel R, Walker-Smith JA. Inflammatory bowel disease. In: Walker WA, Watkins JB, Duggan C, eds. Nutrition in Pediatrics. Hamilton:BC Decker; 2003:635-52.
7. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-30.
8. Hyams JS, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroentrol Nutr 1991;12:439-47.
9. Ferry GD, Kirschner BS, Grand RJ, et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr 1993;17:32-8.
10. Vermeire S, Louis E, Carbonez A, et al. for the Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002;97:2357-63.
11. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592-1608.
12. Bouma G, Strober W. The immunologic and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.
13. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003;124:521-36.
14. Evans WE, Mcleod, HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
15. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73.
16. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
17. Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000;118:859-66.